<DOC>
	<DOCNO>NCT00331058</DOCNO>
	<brief_summary>The primary goal study compare expression key GSK drug target across 4 asthma phenotype healthy subject secondarily evaluate change target expression response 2-week course corticosteroid across 4 asthma phenotype . Each asthmatic subject study undergo two bronchoscopies . Each healthy subject undergo one bronchoscopy .</brief_summary>
	<brief_title>Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Male female subject age 1860 year inclusive screening . A female subject childbearing potential must use effective contraceptive measure describe protocol least one month prior Screening continue use contraceptive measure study completion followup procedure . Non childbearing potential define premenopausal female document ( medical report verification ) hysterectomy surgical sterilisation , postmenopausal woman amenorrheic 1 year estradiol FSH level consistent menopause. ) . Other method include male partner sterile prior female subject 's entry study sole sexual partner female subject . Atopic nonatopic subject Able comprehend nature research protocol relevant medical information ability give write informed consent prior participation study . Able comply requirement restriction list consent form . Available complete study measurement . Read , comprehend , write English sufficient level complete study related material . Additional inclusion criterion steroid naïve intermittent asthmatic Cohort A Have prehistory physician 's diagnosis asthma , exclusion significant pulmonary No significant disease asthma . No history steroid myopathy . No history recent exposure live vaccine past 4 week intention undergo live vaccination prednisolone trial month follow trial . Intermittent asthma FEV1 ≥ 80 % predict . Positive beta agonist reversibility show great 12 % improvement FEV1or great 200ml improvement FEV1 within 30 minute follow administration Albuterol Inhalation Aerosol OR positive PC20 Methacholine Challenge small 16 mcg . Not currently take inhale steroid ( ICS ) , take ICS least 6 month prior screen . A nonsmoker ( demonstrated negative urine cotinine ) least past 12 month pack history ≤5 pack year . Additional inclusion criterion mild moderate persistent asthmatic regular inhaled steroid Cohort B Have prehistory physician 's diagnosis asthma , exclusion significant pulmonary diseases No significant disease asthma . No history steroid myopathy . No history recent exposure live vaccine past 4 week intention undergo live vaccination prednisolone trial month follow trial . Mild moderate persistent asthmatic FEV1 ≥ 80 % predict Asthma symptom range daily less day Positive beta agonist reversibility show great 12 % improvement FEV1or great 200ml improvement FEV1 within 30 minute follow administration Albuterol Inhalation Aerosol OR positive PC20 Methacholine Challenge small 16 mcg . On regular inhaled steroid treatment ( 200500 mcg FP daily equivalent ) . Short long act beta2 agonist , anticholinergies , Leukotriene receptor antagonist allow concurrent medication . A nonsmoker ( demonstrated negative urine cotinine ) least past 12 month pack history ≤5 pack year . Additional inclusion criterion severe persistent asthmatic maximal therapy ; regular oral steroid Cohort C Have prehistory physician 's diagnosis asthma , exclusion significant pulmonary diseases No significant disease asthma . No history steroid myopathy . No history recent exposure live vaccine past 4 week intention undergo live vaccination prednisolone trial month follow trial . Severe persistent asthmatic Subjects least one ( oral steroid ) two ( inhaled steroid ) follow index : 1 . FEV1 &lt; 80 % ( post bronchodilator ) FEV1/FVC ratio &lt; 70 % predict ; 2 . Daily symptom ± nocturnal symptom record diary card runin ; 3. severe exacerbation ( define FACET study Tattersfield 1999 ) ≥ twice year least one last two year , record clinical record Positive beta agonist reversibility show great 12 % improvement FEV1 great 200ml improvement FEV1 within 30 minute follow administration Albuterol Inhalation Aerosol OR positive PC20 Methacholine Challenge small 16 mcg . High dose inhale steroid ( ≥ 1000 mcg FP daily equivalent ) , oral steroid ≤ 20mg prednisolone day equivalent . A nonsmoker ( demonstrated negative urine cotinine ) least past 12 month pack history ≤5 pack year . Additional inclusion criterion currently smoke , mild moderate persistent asthmatic maximal therapy ; regular oral steroid Cohort D Have prehistory physician 's diagnosis asthma , exclusion significant pulmonary No significant disease asthma . No history steroid myopathy . No history recent exposure live vaccine past 4 week intention undergo live vaccination prednisolone trial month follow trial . Smokers ( demonstrate positive urine cotinine ) pack history &gt; 5 pack year Mild moderate persistent asthmatic FEV1 ≥ 80 % predict Asthma symptom less day Positive beta agonist reversibility show great 12 % improvement FEV1or great 200ml improvement FEV1 within 30 minute follow administration Albuterol Inhalation Aerosol OR positive PC20 Methacholine Challenge small 16mcg . On regular inhaled steroid treatment ( 200500 mcg FP daily equivalent ) . ( NB : short long act beta2 agonist , anticholinergies , Leukotriene receptor antagonist allow concurrent medication . ) Additional inclusion criterion healthy volunteer , non asthmatic , non smoker Cohort E Healthy ; define individual free significant cardiovascular , pulmonary ( e.g . tuberculosis ) , gastrointestinal , hepatic , endocrine , renal , haematological , neurological psychiatric disease determine medical history , physical examination clinical chemistry/haematology/urinalysis investigation . • A nonsmoker ( demonstrated negative urine cotinine ) least past 12 month pack history ≤5 pack year . Exclusion criterion : As result medical interview , physical examination screen investigation physician responsible considers subject unfit study . The subject history drug allergy , , opinion responsible physician , contraindicate participation . Subject female pregnant lactating . Having participate within 30 day 5 halflives study receive investigational drug . Having participate within 30 day study invasive procedure . Donation 500 mL blood within previous 56 day intention donate within 56 day end last bronchoscopy . Evidence recent infection would preclude participation steroid trial judgement study physician . The subject may defer late participation . History abnormal bruising bleeding . History alcohol drug abuse within five year . Positive urine test drug abuse include alcohol screen . Abnormal ( clinically significant ) clinical laboratory test result . Medical history cirrhosis , hepatitis C hepatitis B HIV Doing nightshift work change pattern within least 5 day prior study start first follow visit Cohorts A D. This include follow visit 6 12 month . Female subject unwilling unable use appropriate method contraception Those , opinion investigator , risk noncompliance study procedure . Concomitant medication may interfere study procedure evaluation . History hypersensitivity follow medication : Lidocaine , Fentanyl , Versed , Demerol , Midazolam , Epinephrine , Flumanzenil Naloxon . History hypersensitivity bronchodilator ( Albuterol ) ALL WOMEN OF CHILD BEARING POTENTIAL WHO DO NOT WISH TO USE PROTOCOL APPROVED METHODS OF CONTRACEPTION WILL BE EXCLUDED . Additional exclusion criterion steroid naïve intermittent asthmatic Cohort A Subject change asthma medication within 1 month prior screen . Subject asthma exacerbation previous month . Known sensitivity allergy prednisolone . History tuberculosis , glaucoma , epilepsy , severe affective disorder peptic ulceration . Current use use within previous 1 month oral corticosteroid . Current use asthma medication except short act inhaled β2 agonist Current use Methotrexate , cyclosporin , PDE inhibitor , azathioprine immunosuppressive agent , except steroid . Additional exclusion criterion mild moderate persistent asthmatic regular inhaled steroid Cohort B Subject change asthma medication within 1 month prior screen . Subject asthma exacerbation previous month . Known sensitivity allergy prednisolone . History tuberculosis , glaucoma , epilepsy , severe affective disorder peptic ulceration . Current use use within previous 1 month oral corticosteroid . Current use Methotrexate , cyclosporin , PDE inhibitor , azathioprine immunosuppressive agent , except steroid . Additional exclusion criterion severe persistent asthmatic maximal therapy ; regular oral steroid Cohort C Subject change asthma medication within 1 month prior screen . Subject asthma exacerbation previous month . Known sensitivity allergy prednisolone . History tuberculosis , glaucoma , epilepsy , severe affective disorder peptic ulceration . Current use use within previous 1 month oral prednisolone equivalent great 20mg daily . Current use Methotrexate , cyclosporin , PDE inhibitor , azathioprine immunosuppressive agent , except steroid . Subjects avoid medication opinion physician might interfere either safety subject interpretation result ( e.g . antiinflammatory drug ) Additional exclusion criterion currently smoke , mild moderate persistent currently smoke asthmatic regular inhaled steroid Cohort D Subject change asthma medication within 1 month prior screen . Subject asthma exacerbation previous month . Known sensitivity allergy prednisolone . History tuberculosis , glaucoma , epilepsy , severe affective disorder peptic ulceration . Current use use within previous 1 month oral corticosteroid . Current use Methotrexate , cyclosporin , PDE inhibitor , azathioprine immunosuppressive agent , except steroid . Additional exclusion criterion healthy volunteer , non asthmatic non smoker Cohort E The subject history breathing problem adult life ( i.e . history asthmatic symptom ) . Screening lung function test ( FEV1 ) perform confirm normal lung function parameter ( ≥80 % predict ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Severe Asthma bronchoscopy</keyword>
</DOC>